Moderna to start local production of COVID-19 mRNA vaccine in Canada
The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses.
Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility with the collaboration of the Canadian government.
The collaboration aims to provide Canadians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure.
The facility is intended to also be activated on an urgent basis to support Canada with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model. ■